I want to use my last post as I am a paid subscriber in this board to say that the only thing I can come up now to explain the low share price now is of a conspiracy one which may be just an entertaining:

Since no other major funds have paid attention to the company except for those which have already had a major position, when news like this (always fuzzy or not transparent or straightforward due to its nature) broke out, not many funds really understand what it really means; on the other hand, the shorts funds have always thought in a biased way just as the long funds have always thought in an equally biased way in different direction, short funds have continually shorted shares they can have to subdue the price, hoping one day the company will go bankrupt, while the long funds already in major positions don't want to take a bit of more risk, decided to sit it out for a definite sign.

So there is still a depressed price.

The good thing if God willing, is that if that definite sign is out, both longs and short funds and the general public and lots of new funds will compete with ever dwindling share counts, and the price will go much much higher than if the price now were in the teens or twenties!

Just want to add: some people still ask why the halt for screening new patients? Some people have provided various reason.

Simply put, if AA is in the process, or if the company via CRO knows the results have med prespecified requirement, continually screening, recruiting and enrolling patients according to the protocol is simple unethical.

So I believe the existing patients, ie those already enrolled in the trial are continually being treated according to protocol while no new patients are screened and recruited, and any patients in the pipeline are not randomized, until consultation with FDA, etc. is complete with directive results!

It could be AA granted or continue with the trial.

But, some other possibility still exists between the above and a safety issue.

I believe this time what you say is truth to yourself and actually reflect what is your position: light yet tons of peripheral investigations, opinions and comments.

What happening is DMC's recommendation to the company via CRO halt for efficacy and what is going on is the consultation with FDA, etc, on whether an AA or outright approval is a possibility or whether the trial needs just continue, as the universal or trial-wide halt is now in effect, not only in Germany.

If there is safety concern or actual safety consequence, FDA will immediately place a hold and the company will stop treating patients enrolled in the trial, let alone screening, etc.until investigation into such an issue is complete.

The time for the first interim results and recommendation is just right, and the company has let us in the dark for so long a time; as the price is high, the company has not yet raised any new funds, ... all point to such a happening.

Now the only thing makes me think otherwise, or there must be other something (possibility) up in the air is that the market has not responded the way that an AA is in the process, otherwise the price must have been in the teens or twenties at least!

Either way, as long as safety issue is ruled out, holding or adding some may not be a bad idea!

Never check back my English in most of my board writing, so sorry for any errors or inconvenience!

Thanks Senti. From the beginning I was convinced it might be a halt due to AA consultation with FDA and other authorities in EU if the halt is not universal or at least HE if the halt is only for Germany.

Now thanks to your guys hard work and the possibility of AA just gets stronger.

Either way or maybe it just some adjustment of the trial which I have not seen at this time. I have determined as always to see the light, the approval of DCVac platform as an effective cancer treatment!

That day may just come earlier than most have expected!

How ironic, how funny, I like it.

BTW, I went through that whole process with your IV friend in 2011. All patients in the trials not only the one in which the safety issue occurred but all trials using the same vaccine called Stimuvax at the time were stopped of any further treatment with the vaccine.

Above is just additional information for those who are so busy to sort through the news I provided.

Just back from my long vacation and a quick trip to Southern China thereafter.

Seen so many posters have replied to your endless FUD, I am going to take this exception to reply to your post (no further replies shall be expected):

If it is due to safety issue, the company would not only stop screening patients, it would have to stop recruiting and treating any patients (existing and potential). See example below:

" Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono

SEATTLE, March 23, 2010 /PRNewswire via COMTEX News Network/ -- ONCOTHYREON TO HOLD TELECONFERENCE AT 5:00 PM EDT

Oncothyreon Inc. (Nasdaq: ONTY) today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., have temporarily suspended the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine). The suspension is the result of a suspected unexpected serious adverse reaction in a patient with multiple myeloma participating in an exploratory clinical trial. This decision was taken in alignment with the U.S. Food and Drug Administration's (FDA) clinical hold placed on the Investigational New Drug (IND) application for Stimuvax.

The suspension affects the Phase 3 clinical program for Stimuvax, including the START and INSPIRE trials in non-small cell lung cancer (NSCLC) and the STRIDE trial in breast cancer. Further recruitment of patients into all trials actively recruiting patients and ongoing treatment with Stimuvax in these trials are suspended.

"Patient safety is of paramount importance to Merck Serono and to Oncothyreon," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "We understand that Merck Serono is working closely with the FDA, other regulatory agencies and the patient's physicians to evaluate the implications of this adverse reaction and to determine an appropriate course of action."

The exploratory trial in multiple myeloma is designed to investigate the mechanism of action of Stimuvax and the effect of cyclophosphamide on regulatory T cells, which may affect the response to the therapeutic vaccine. The adverse event occurred in a patient receiving a more intensive regimen of low-dose cyclophosphamide than is utilized in the Phase 3 program. The patient developed an encephalitis, or inflammation of the brain. No other events of this kind have been reported in other trials of Stimuvax to date.

Conference Call Information

Oncothyreon will host a conference call and webcast today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. To participate in the call by telephone, please dial 877-280-7291 (United States) or 707-287-9361 (International). In addition, the call is being webcast live and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.

About Stimuvax

Merck KGaA has an exclusive world-wide license from Oncothyreon for Stimuvax. Merck KGaA is investigating the use of Stimuvax(R) (BLP25 liposome vaccine) in the treatment of NSCLC. The vaccine was granted fast-track status in September 2004 by the FDA. Stimuvax is being developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc.

START is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study that will evaluate patients with documented unresectable stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study will involve more than 1,300 patients in approximately 30 countries.

The INSPIRE study is a multi-national, Phase 3, double-blind, placebo-controlled, randomized clinical trial designed to evaluate the efficacy, safety and tolerability of Stimuvax in subjects suffering from unresectable, stage III NSCLC and demonstrating either stable disease or objective response following primary chemo-radiotherapy. The study will enroll approximately 420 unresectable, stage III NSCLC patients across China, Hong Kong, Korea, Singapore and Taiwan.

STRIDE is a randomized, double-blind, controlled, multi-center Phase III study designed to determine if Stimuvax(R) can extend progression free survival in patients treated with hormonal therapy who have inoperable, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study."

The link is here: http://ir.oncothyreon.com/releasedetail.cfm?releaseid=453976

I keep adding shares and options since this drop. Today I also add 20 2017 target $10 call contracts at $2.15 a piece.

I will continually urge people not to reply to your posts, since you are a person proven not trustworthy (moderator it's my genuine opinion, please not think it is a personal attack and name calling. Thank you).

Too busy, not time to post further, and life is beautiful, not intend to waste my time in thing like this.

Yes that would be a concern. My understanding is that any recommendation received by the company is a material news and the company must convey to the general public within 72 hours.

In my opinion, the window for that to happen is from now to late October, and the result would be more than 80% for a continue, and about 15% for stop for efficacy or about 5% for stop for safety concern, but I love a positive surprise!

In the meantime, I expect we will have some other positive news.

Thanks TC_Trader.

Hope shorts' last standing nerve collapse soon, either at $15 or $20.

Good day.

Does that surprise you? I bet yes it does. Keep your eye, yes just one, open wide. We will be in the territory NWBO deserves, which is just catching up with its peers.

I don't want give a specific number, and you should do a bit of DD if you are interested.

Now go delete this post, Mr. TOB.

You are right for most small biotech companies under normal circumstances, but it has shown this situation have no longer applied to NWBO.

Just review the last two financings from Neil Woodford. Each time we had a financing, the stock price moved higher due to the positive terms of the financings.

We all owe something to Neil Woodford. He is an amazing guy with a vision.

All in all, NWBO may not need any financing any more due to conversions, possible partnership deals, or even income from HE.

The hard and cold truth is still that NWBO's share price is still severely undervalued at $12.

Everything should be put under that perspective! BTW, if we keep going like this for a few more days, a squeeze has to happen!

It has puzzled me and sometimes made me angry seeing posters (long shareholders) guess what is really behind the price appreciation any time the price is going up. It seems they are trying to time the market at such a low price of $11.

Well, if you are long, and have done your DDs and believe either L or D or both L and D will be successful in developments to become blockbuster cancer treatments, why the shaky hands and minds of efforts guessing a price which is far less than its due price.

I said it before, and I am going to say it again. If JUNO can have around $6 billion market cap in such early development, why cannot we have the same MC?

That would give us around $80 a piece. At today's price of $11.39, it may be fun to have this or that speculation, but really, give me a break!

Wake me up when the price heats at least $30, where I will keep a watchful eye on it. Now it is summer vacation!

Fair enough, Evaluate that nobody would and should have that kind of information as you stated!

In biotech investing, only things matter are 1) does the company has a solid support financially? [My answer is yes. It is backed by Sir Neil Woodford, and others]; does the company's development is fundamentally sound and in competitive advantage [my answer is a yes, backed by all the information we have had today]; and does the company's market cap has been reflected fairly compared to its true market potential and that of its peer? [My answer is no, and it is well off at this point of time]

I don't care day to day up and down in price and from time to time throw a sword at someone who understandably swings trading. My thesis has had no change.

I have too many shares and call options, but I am ready to buy more call options if the price goes down; on the other hand, if the price continually goes up, I am okay with my decision of no action until the price reach certain high territory, for instance $30.

Not intended to reply on behalf of OTCPimp, but below is my answer:

The trump card might be stop for efficacy of L trial (why subject of ASCO subject had changed to excluding of L)in the near future, or

The trump card might be FDA's breakthrough designation for D, or

The trump card might be a big announcement of cooperation with a BP, or

The trump card might be a leak information about a buyout intent launched by a BP, or

The trump card might be completion of enrolment of L trial (about 15 sites have completed and now listed as "active not recruit patients" or simply "complete," or

The trump card might be the long awaiting HE price negotiation news, or

The trump card might be the completion of the long awaiting UK designation, or

The trump card might be a well-known Wall Street investor having invested significant amount of money in the company, or

The trump card might be simply unknown at this time!

I constantly think about the reason why I should sell a single share at this time before the share price is at least close to our nearest peer CLDX at a market cap of about 2.3 billion today, which will give us a share price of about $33.

Maybe you can give me some reason to consider!

Probably incurred after market close (after hours) at a price accommodating the day's price. Big guys do this all the time.

Please continue with your DD until we are in the fair price range of $39 ~ $81 compared to our peers.

BTW Pyrr, it seems you now have a better and prettier cover than what you used to have.

Place your hand on the Holy book, and say "I am not Pyrr."

Oh, I should have not asked that, with your drinks too much each night; what I can expect?

Why the title of the presentation at ASCO had been changed from including both D and L to only including D?

As I speculated in yahoo board (not post often now since I had tired of reading mostly useless posters some time ago. The same applies in this board), the events of 149 patients for the first interim analysis might have been reached just after the first time the title shown up in the public eye (thus the change of the title soon after).

are we waiting for DMC's recommendation now? !

If this is true, the price will continually climb for a couple of two more months until DMC comes up with a recommendation.

On the other hand, I also personally speculate that one or two Wall Street big names, either of investment firms or individual hedge fund/fund managers will be known to the public for taking a significant position besides UK's Woodford.

If either of these events happen, the price can easily go up to $20 and higher in a short period of time, excluding other major catalysts such as UK's final stage designation, HE price negotiation, D P2 launches, partnership deals with CI company...

I have a few minutes today so I have my comments in brackets below:

"A couple of points:
First I own 23K shares and am proud of it.

[you really think so. Judged by your constant confusing rants, it would be more accurately to say I have 23 shares now and would like to have about 23k someday. Remember you were a crying baby blame the drop of pps last year squarely on your buddy Pyrr, a pumper at that time ?]

......

I would like to see more balanced discussion and that is why I enjoyed Pyrr's commentary. But I am deeply troubled by him, he promised not to come back on until July, that did not happen. In fact he came on at the impeccably timed to stop the runup on the latest PR similar to AF did in the past. If he was sincere he could have done it anytime after inorder to opine like anybody else. But he felt the need to post for one reason imho and that was to affect the pps. So I believe he absolutely outed himself since he admitted he was no longer a shareholder why then post an AF timed hit piece? Looking at the time he spent doing ii is also suspect.

Many here like I wonder why he was totally opposite last year and now I realize for the same reasons to effect the pps while he owned the stock. I often asked how is tha the can spend so much time here and what was his background and was always ignored.

[You have observed the obvious and yet you still think his opinion could serve as a balance or check. In the real world, are you going to trust anyone who has been proven a crook?

As far as your wondering of why, I have concludes long time ago that Pyrr has since worked as a BP's pawn just as my long time fellow investor AVII who I came to know when we were hung up in ONTY board long time ago. He also went through the same process from a pumper to a foot soldier working for big pharm, either directly or indirectly (such as on commissions).]

This is what I want to know too for God sake. Last post for today, back to day work!

Hello, young man again,

You have freedom of speech. So if you want to write a paper of any nature, go ahead as long as it is accepted. Of ource, SA is a low bar outlet, you can easily get it out!

I have one thing to remind you that the stock price is normally not influenced by any paper (post, commentary or the like) unless there is a force behind it, either planned in advance or taking advantage of any occurring occasion, such as the publication of an article, analysis, commentary, etc.

Why sometimes AF seems so powerful in influencing stock price of some small biotech companies, even if his commentary or opinion is just plain lie or full of accusations or of a bunch of randomly picked negative words? It is because there is always a force behind it.

Luckily we have well passed that stage thanks to the awareness of the general market, spearheaded by Woodford.

So as all of us know, but sometimes we all forget it: the market is moved only by big money!

Young man, so can I suggest you go with your money! Why waste valuable time in a stock you have no position, and instead of taking a good care of the ones you have position!

The behavior of yours reminds me of that of Wolf in this board too.

Yes,

This is my last post for today!

Good luck and beware of FUD!

I will add to my point in rebuke your point:

Have you had chance to compare the current (or recent) market caps of JUNO, KITE, BLUE, CLDX and NWBO. How crazy are their market caps and how outrageous is our market cap!

I know humans for thousands of years have still debated egg and chick who came first. I have no interests in any meaningless debate!

My money has invested. The developments of market, nwbo have been carefully watched.

That's enough for me now.

" I haven't sold anything yet, but the higher we go the more cautious I get."

How old are you?

He certainly did which can be seen from his energetic renewed FUD! Oh we also have that wolf who claimed to hold 40 something thousands of shares (what kind of English is this?)while has done anything possible to against his or her or its long shares (again what kind of English is this? It is difficult to understand!)

Oh, what a world are we living?

Now I have more than one half million dollars of paper profit! Should I sell some? LOL!

Nothing wrong with taking some profit and it is always better to see shares change hands from the weak to the strong.

Can FUD changes share price? But it certainly have made a lot of posters reveal their true identities.

Pity!

I have thrown out that word to Pyrr some time ago and now I am going to to use my last post for today to throw it out to you, plus one more word (both are in capital cases):

Dynamics has LONG changed!

Pyrr has come out of his shadow or now it's your time!

It is most likely those puts will be expired worthless as the sellers might have used the premiums to buy those April calls.

The call options have been steadily exercised recently as the seller scrambled to either surrender own shares or buy shares from open market to deliver to the buyer.

Of course a small fraction of those transaction comes from retails!

I cannot help but reply to your exaggerated reply by this written in Yahoo board by arhdan9 • Apr 9, 2015 6:21 PM

"A Beautiful Battle Waged by Sir Woodford & He Has Been Winning_Analysis of Abnormally High Volumes of Option Trading
We all know there are huge volumes of April $7 strike call options traded and huge July $6 strike put option traded so far. Although there are numerous possibilities in terms of what really its implications. But it seems the most likely possibility in general is that Sir Woodford had initiated both these two large pools of option trading:

He bought those calls funded by his selling of those puts since he believes the good data are coming and his financial strength behind his commitment or conviction of going long NWBO on the context of knowing that he would had a major financing deal with the company , i.e., the recently announced $40 million deals with the company.

On the other hand, the shorts thought that the company was in desperation of needing funding to fund its existing L trials, the future D trials, etc., and did not believe the company could get any favorable deal with anybody. They initiated those call selling (to Woodford, etc. unfortunately for the shorts) hoping to pocket the premiums while driving the price down further. Again the shorts thought the price would further decline by July after the ASCO hype withered, so they took the bite of those July put selling (from Woodford, etc.) and ended up of bought those puts.

Now, we have known Sir Woodford has been winning the battle as the share price steadily and continually appreciated: he has been either exercising his deep in money call options or simply closing those profitable call operation as the shorts have to deliver those shares to him via either buying in the open market at increasingly higher price as each day passes by.

The irony of the situation is that the currently share price appreciation may be actually in part (or a major part) is fueled by the shorts. LOL!

Of course, because of the dynamics shift in favor longing the stock, more and more retail investors have firmed in the support of the long institutions represented by Sir Woodford."

That's not true, senti. One or two brokers may not have shares to lend, but there are still shares there to anyone who has appetite to borrow.

It seems that it is difficult to find some persons who do have that kind of appetites!

From interactive Broker as of 10:36am this morning:

"Symbol: NWBO
Availability: 30'000
Exchanges: NASDAQ"

Glad to see you have awakened instead of blaming your investment misery on his advice or analysis!

Best of your posts I have read so far. Are you a different person know?

Your impatience regarding HE negotiation is nonsense, and its relation with DNDN is outrageous!

Let the German stand in heat! NWBO should never give an inch to the German in terms of price which I think is the sticky point.

It is because the slow moving process of HE price negotiation that I have added to my already huge (128,000 shares plus lots of $3 and $7 leap call options I bought last summer).

Ever increased confidence is never a bad sign, who care your or his or her impatience.

I have told that little Pyrr long ago that DYNAMICS has changed. To invest in a company requires micro-analysis but more macro-analysis.

I have pity of those who constantly and endlessly bring some trivial things here to FUD!

I am not an expert either, but have traded options for years. My understanding is that this situation usually happens when there is not a high volume.

IMHO, because of this unusually low premium (almost with no time values for almost two years of time), it is a real bargain for buyers of these leap calls. Of course if you don't believe the success of either L or D, then don't buy any leap calls. In addition, time values are relatively insignificant for in the money leap calls compared to out of money calls!

I have lots of leap call options at strikes $3, and $7 along with a very large number of shares.

Nonetheless, things can change very quickly, making leap options very expensive.

The last I want to say is that compared to the manipulation of shares, option manipulation is more rampant!

Thank you for your honesty.

Yes you all have failed, Cramer, AF, you sir, along with a long list of others with the first letter beginning with K, I, A, etc.

But, not get scared! This is just a combat in a grand campaign.

Please keep your spirit up and high for the next combat, and the next next combat.

We will see how you are doing when price hits $30, $60,

Or even $1,000.

I am a believer!

You two make a great but flawed team, along with some of endless posters here we all know, one started wit a letter of I, other with a K, one other a S, and maybe even the delicate one with a R.

But I have to declare all the statements above are just my speculations on my personal observation and dozens of years of investment experience.

Happy investing, longs or shorts. At the end, what all that matters is truth!

See you tomorrow!

I have a friend who is the envy of our local investment club for his spectacular investment successes and wonders.

At the end, he was broken, and fired from his position because he temporarily moved some company's money into his margin accounts.

Your behavior sometimes make me think about that poor guy!

Happy to see your somewhat adapted comments. That's a smart guy used to do, not a Ph.D. like me. Anyhow, I know you and your stand, so no matter what.

"The whole problem really is that they stopped getting scans after 2 months. Continued imaging at 4 and 6 months would likely have revealed a number of additional psPD in the "undetermined" cohort."

You are probably right, but as usual, your problem (or why people are judged you harshly sometimes is really due to your own fault) is that you only pick the one you like while intentionally leave the other half unnoticed. For instance, your statement "would likely have revealed a number of additional psPD in the "undetermined" cohort" is equally applicable for rapid progressive patients, etc.

I thought you promised not to comment anymore?

Not all, at least maybe you should exclude me from that group. I, an immigrant, earned a Ph.D. in engineering in an "Ivy," and have worked dozens of years in various sectors, including industry, academics, and even a lawyer firm.

But don't challenge me with an English contest!

Anyhow and anyway (do those two words the most hated in the world?), cheer for today's great results and your mostly true analysis and observation.

We are heading to higher land, and we should leave plenty of time for market to respond!

Where is our "expert,"? with his analysis based on definite 24 pseudo progression patients in 55 information arm. Now I cite a yahoo post below:

"Yes, the idiot in IHub has made the number of pseudo progression patients at 24 as if it is a fact. Now we know only one patient is confirmed to be pseudo pression. Yes, as you said for most conservative point of view (impossible) by assuming all those 25 indeterminate patients are pseudo, the results are sill unbelievable positive and unheard of."

ditto! Guess you can still use other names. LOL.

Seriously, please keep your promise cause I would prefer to reading nonsense instead of your warped sophistication!

This is my last for today!

How he know only data on some patients are going to be talked about? He should have a quality grapefruit juice instead of the shady one!